AU2001234968A1 - Diagnostics and therapy of epstein-barr virus in autoimmune disorders - Google Patents

Diagnostics and therapy of epstein-barr virus in autoimmune disorders

Info

Publication number
AU2001234968A1
AU2001234968A1 AU2001234968A AU3496801A AU2001234968A1 AU 2001234968 A1 AU2001234968 A1 AU 2001234968A1 AU 2001234968 A AU2001234968 A AU 2001234968A AU 3496801 A AU3496801 A AU 3496801A AU 2001234968 A1 AU2001234968 A1 AU 2001234968A1
Authority
AU
Australia
Prior art keywords
epstein
diagnostics
therapy
barr virus
autoimmune disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234968A
Inventor
John B Harley
Judith A. James
Kenneth M. Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU2001234968A1 publication Critical patent/AU2001234968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001234968A 2000-02-09 2001-02-09 Diagnostics and therapy of epstein-barr virus in autoimmune disorders Abandoned AU2001234968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/500,904 US7273613B1 (en) 1997-01-13 2000-02-09 Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
US09500904 2000-02-09
PCT/US2001/004191 WO2001058481A2 (en) 2000-02-09 2001-02-09 Diagnostics and therapy of epstein-barr virus in autoimmune disorders

Publications (1)

Publication Number Publication Date
AU2001234968A1 true AU2001234968A1 (en) 2001-08-20

Family

ID=23991411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234968A Abandoned AU2001234968A1 (en) 2000-02-09 2001-02-09 Diagnostics and therapy of epstein-barr virus in autoimmune disorders

Country Status (3)

Country Link
US (1) US7273613B1 (en)
AU (1) AU2001234968A1 (en)
WO (1) WO2001058481A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
EP2325195A1 (en) 2009-11-23 2011-05-25 Toscana Biomarkers S.r.l. Viral citrullinated peptides and uses thereof
WO2011127299A1 (en) * 2010-04-09 2011-10-13 The General Hospital Corporation Methods for the treatment of autoimmune diseases
WO2014029816A1 (en) * 2012-08-22 2014-02-27 Universität Basel Vizerektorat Forschung Anti-c1q epitope elisa

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4692416A (en) 1982-12-03 1987-09-08 Yeshiva University Monoclonal antibodies reactive with shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus
US4707358A (en) 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US4654419A (en) 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
EP0173254B1 (en) 1984-08-23 1991-07-24 Hans Joachim Wolf Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens
US4784942A (en) 1984-11-05 1988-11-15 The Board Of Regents For The University Of Oklahoma Monoclonal antibodies against autoimmune RNA proteins
US4865970A (en) 1986-02-28 1989-09-12 Hoffmann-La Roche Inc. Method of detecting ribosomal protein antibodies in systemic lupus erythematosus
CA1313818C (en) 1987-06-03 1993-02-23 Ross Leon Coppel Nuclear antigen la
ES2053712T3 (en) 1987-10-21 1994-08-01 Akzo Nv A REACTIVE PROTEIN ANTIGEN AND FRAGMENTS OF THE SAME.
NL8703107A (en) 1987-12-22 1989-07-17 Nederlanden Staat POLYPEPTIDES AND DERIVATIVES THEREOF, AND THEIR USE THEREOF IN PHARMACEUTICAL AND DIAGNOSTIC PREPARATIONS.
US5312752A (en) 1989-07-31 1994-05-17 Trustees Of Boston University Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
WO1991011718A1 (en) 1990-01-31 1991-08-08 Regents Of The Board Of The University Of Oklahoma Assays and treatments for autoimmune diseases
AU7958891A (en) 1990-05-07 1991-11-27 Oklahoma Medical Research Foundation Nucleotide sequence encoding a 52 kda ro/ssa autoantigen
FR2663034B1 (en) 1990-06-06 1995-04-21 Neosystem Sa PEPTIDES OF THE SM-D ANTIGEN AND THEIR USE IN PARTICULAR FOR THE DIAGNOSIS OF DISSEMINED LUPUS ERYTHEMATOUS.
DE69327239T2 (en) 1992-04-13 2000-05-11 Oklahoma Med Res Found METHODS AND REAGENTS FOR DIAGNOSIS OF AUTOANTIBODIES
WO1994002509A1 (en) 1992-07-15 1994-02-03 Rijksuniversiteit Leiden Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
AU667745B2 (en) 1992-09-14 1996-04-04 Akzo Nobel N.V. Epstein-barr virus peptides and antibodies against these peptides
WO1994021669A1 (en) 1993-03-18 1994-09-29 Medclone, Inc. Antigen related to inflammatory diseases
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
IL113484A0 (en) 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
AU7349496A (en) 1995-05-25 1996-12-11 Oklahoma Medical Research Foundation Method for treatment of SLE

Also Published As

Publication number Publication date
US7273613B1 (en) 2007-09-25
WO2001058481A2 (en) 2001-08-16
WO2001058481A3 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU4244200A (en) Multi-functional therapeutic compress and methods of using the same
AU2001264638A1 (en) Functional separation of internal and external controls in network devices
AU2001286171A1 (en) Human cDNAs and proteins and uses thereof
AU4987700A (en) Polymerized modified particles and methods of making the same
AU8079901A (en) Promyostatin peptides and methods of using same
AU2002315166A1 (en) Sir2alpha-based therapeutic and prophylactic methods
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
AU2001272840A1 (en) Adjustable chair and method of use
AU7612000A (en) Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
AU2002217393A1 (en) Educated nk t cells and their uses in the treatment of immune-related disorders
AUPQ155799A0 (en) Therapeutic methods and uses
EP1416957A4 (en) Treatment of immune disorders and b cell disorders
AU2001285683A1 (en) Mild enrichment of foetal cells from peripheral blood and use thereof
IL153201A0 (en) Methods of treating viral diseases with il-18 and il-18 combinations
AU2001234968A1 (en) Diagnostics and therapy of epstein-barr virus in autoimmune disorders
AU2001261375A1 (en) Human caspase-12 materials and methods
IL146465A0 (en) Substituted 3-pyridyl-4-arylpyrroles and related therapeutic and prophylactic methods
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2000239273A1 (en) Systems and methods of viral marketing
EP1263935A4 (en) Scytonemin and methods of using thereof
AU5565401A (en) Materials and methods for the treatment of depression
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2217399A (en) Promoting mobilization and catabolism of lipids